Brief: Avalo Therapeutics Announces First Patient Dosed In The Avtx-803 Pivotal Trial (Ladder) For The Treatment Of Leukocyte Adhesion Deficiency Type Ii (Lad Ii)

Avalo Therapeutics

02/08/2022 13:03

Aug 2 (Reuters) - Avalo Therapeutics Inc  AVTX.O :
    * AVALO THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN THE
AVTX-803
PIVOTAL TRIAL (LADDER) FOR THE TREATMENT OF LEUKOCYTE ADHESION
DEFICIENCY TYPE II (LAD II)

Source text for Eikon:  ID:nGNX7LYGVn 
Further company coverage:  AVTX.O 

 ((reuters.briefs@thomsonreuters.com;))